Table 1.
Demographic and clinical features of study population.
| Male (%) | 41 (50.0) |
| Age, mean (SD), yr | 45.9 (19.1) |
| Disease duration, median (IQR), yr, n (%) | 5 (2–13) |
| >6 | 29 (35.4) |
| 4–6 | 21 (25.6) |
| ≤3 | 32 (39.0) |
| Disease location, n (%) | |
| Proctitis | 8 (9.8) |
| Left-sided | 38 (46.3) |
| Extensive colitis | 36 (43.9) |
| Partial Mayo score, median (IQR) | 4 (3-5) |
| Remission (partial Mayo score < 2) n (%) | 1 (1.2) |
| Mild activity (partial Mayo score 2–4) n (%) | 53 (64.6) |
| Moderate activity (partial Mayo score 5–7) n (%) | 28 (34.2) |
| Increased C-reactive proteina, n (%) | 10 (11.0) |
| Charlson Index, median (IQR) | 0 (0–2) |
| Primary concomitant medications, n (%) | |
| Infliximab | 1 (1.2) |
| Adalimumab | 3 (3.7) |
| Golimumab | 3 (3.7) |
| Vedolizumab | 3 (3.7) |
| Azathioprine | 7 (8.5) |
| Salazopyrin | 2 (2.4) |
| Mesalazine | 44 (53.7) |
| Mesalazine MMX | 10 (12.2) |
| Escherichia coli Nissle | 1 (1.2) |
| Beclometasone dipropionate | 1 (1.2) |
| No oral or systemic therapy | 7 (8.5) |
| Previous anti TNF agents or azathioprine, n (%) | 6 (7.1) |
| Topical therapy, n (%) | |
| Mesalazine | 42 (51.2) |
| Beclometasone Mesalazine + beclometasone | 8 (9.8) 3 (3.7) |
| Use for budesonide-MMX therapy, n (%) | |
| Clinical relapse | 39 (47.5) |
| Partial or not satisfactory response to previous therapy | 32 (39.0) |
| Side effects of the previous therapy | 3 (3.7) |
| Alternative use to systemic corticosteroids | 8 (9.8) |
a
Normal value < 10 ml/L.
IQR: interquartile range.